Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Coagulation | 4 | 2023 | 22 | 1.870 |
Why?
|
| Factor XIa | 3 | 2022 | 4 | 1.250 |
Why?
|
| Anticoagulants | 4 | 2023 | 97 | 1.240 |
Why?
|
| Factor XIIa | 2 | 2023 | 2 | 1.100 |
Why?
|
| Thrombosis | 2 | 2022 | 61 | 0.880 |
Why?
|
| Pentamidine | 2 | 2019 | 9 | 0.850 |
Why?
|
| Fibrinolysis | 1 | 2019 | 1 | 0.720 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2019 | 34 | 0.690 |
Why?
|
| Lipid Bilayers | 3 | 2007 | 66 | 0.620 |
Why?
|
| Thermodynamics | 4 | 2010 | 207 | 0.590 |
Why?
|
| Membrane Proteins | 3 | 2014 | 486 | 0.530 |
Why?
|
| Antineoplastic Agents | 4 | 2015 | 756 | 0.520 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 52 | 0.500 |
Why?
|
| Models, Molecular | 9 | 2015 | 751 | 0.480 |
Why?
|
| Prothrombin Time | 2 | 2023 | 9 | 0.410 |
Why?
|
| Biomimetic Materials | 1 | 2007 | 23 | 0.310 |
Why?
|
| Alamethicin | 1 | 2006 | 8 | 0.280 |
Why?
|
| Membrane Lipids | 1 | 2006 | 31 | 0.280 |
Why?
|
| Allosteric Site | 2 | 2022 | 11 | 0.270 |
Why?
|
| Neoplasms | 1 | 2015 | 1033 | 0.260 |
Why?
|
| Amides | 1 | 2005 | 66 | 0.250 |
Why?
|
| Catalytic Domain | 2 | 2022 | 97 | 0.240 |
Why?
|
| Thrombin Time | 2 | 2020 | 2 | 0.230 |
Why?
|
| Partial Thromboplastin Time | 2 | 2020 | 8 | 0.230 |
Why?
|
| Animals | 13 | 2023 | 14307 | 0.230 |
Why?
|
| Humans | 15 | 2023 | 34853 | 0.230 |
Why?
|
| Ethacrynic Acid | 1 | 2022 | 1 | 0.220 |
Why?
|
| Factor XIIIa | 1 | 2022 | 1 | 0.220 |
Why?
|
| Models, Biological | 1 | 2006 | 642 | 0.220 |
Why?
|
| Antifibrinolytic Agents | 1 | 2022 | 3 | 0.220 |
Why?
|
| Factor IX | 1 | 2022 | 1 | 0.220 |
Why?
|
| Computer Simulation | 4 | 2010 | 347 | 0.200 |
Why?
|
| Skin Neoplasms | 3 | 2011 | 151 | 0.200 |
Why?
|
| Drug Design | 2 | 2019 | 154 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2011 | 117 | 0.190 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2020 | 28 | 0.180 |
Why?
|
| Hydroxamic Acids | 1 | 2019 | 30 | 0.180 |
Why?
|
| Factor VIIa | 1 | 2019 | 2 | 0.180 |
Why?
|
| Blood Coagulation Tests | 1 | 2019 | 5 | 0.180 |
Why?
|
| Factor Xa | 1 | 2019 | 3 | 0.180 |
Why?
|
| Thrombin | 1 | 2019 | 24 | 0.180 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 105 | 0.180 |
Why?
|
| Sulfonamides | 1 | 2019 | 75 | 0.170 |
Why?
|
| Cell Proliferation | 5 | 2020 | 1149 | 0.170 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2017 | 7 | 0.160 |
Why?
|
| Flavanones | 1 | 2016 | 7 | 0.140 |
Why?
|
| Skin Aging | 1 | 2016 | 10 | 0.140 |
Why?
|
| Sunscreening Agents | 1 | 2016 | 9 | 0.140 |
Why?
|
| Hydrogen Bonding | 2 | 2007 | 119 | 0.140 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2015 | 6 | 0.140 |
Why?
|
| Carbonic Anhydrase II | 1 | 2015 | 2 | 0.140 |
Why?
|
| Keratinocytes | 1 | 2016 | 65 | 0.140 |
Why?
|
| Bile Acids and Salts | 1 | 2015 | 31 | 0.130 |
Why?
|
| Dizocilpine Maleate | 1 | 2015 | 45 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 94 | 0.130 |
Why?
|
| Ultraviolet Rays | 1 | 2016 | 116 | 0.130 |
Why?
|
| Protein Structure, Secondary | 2 | 2006 | 172 | 0.130 |
Why?
|
| Piperidines | 1 | 2015 | 76 | 0.130 |
Why?
|
| Protein Conformation | 2 | 2006 | 350 | 0.130 |
Why?
|
| Mutation | 2 | 2017 | 1023 | 0.130 |
Why?
|
| Antigen-Presenting Cells | 1 | 2014 | 30 | 0.130 |
Why?
|
| Structure-Activity Relationship | 4 | 2019 | 376 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 68 | 0.130 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2015 | 131 | 0.130 |
Why?
|
| Bibenzyls | 1 | 2014 | 4 | 0.130 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 16 | 0.120 |
Why?
|
| Signal Transduction | 2 | 2014 | 1802 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 528 | 0.120 |
Why?
|
| Thiazoles | 1 | 2014 | 71 | 0.120 |
Why?
|
| Glycyrrhiza | 1 | 2013 | 1 | 0.120 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2013 | 2 | 0.120 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2013 | 31 | 0.120 |
Why?
|
| Mice | 8 | 2020 | 5668 | 0.120 |
Why?
|
| Pyridines | 1 | 2014 | 113 | 0.120 |
Why?
|
| Binding Sites | 4 | 2017 | 597 | 0.110 |
Why?
|
| Isoflavones | 1 | 2013 | 125 | 0.110 |
Why?
|
| Melanoma | 1 | 2013 | 91 | 0.110 |
Why?
|
| DNA | 1 | 2015 | 549 | 0.110 |
Why?
|
| Xanthenes | 1 | 2011 | 11 | 0.110 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 341 | 0.110 |
Why?
|
| Epidermis | 1 | 2011 | 26 | 0.100 |
Why?
|
| Cell Line, Tumor | 5 | 2020 | 2128 | 0.100 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 20 | 0.100 |
Why?
|
| Sunlight | 1 | 2011 | 46 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 97 | 0.100 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2011 | 14 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 90 | 0.100 |
Why?
|
| Flavonoids | 1 | 2011 | 78 | 0.100 |
Why?
|
| Flavonols | 1 | 2011 | 15 | 0.100 |
Why?
|
| Phosphatidylinositols | 1 | 2010 | 12 | 0.100 |
Why?
|
| Inositol | 1 | 2010 | 20 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 242 | 0.090 |
Why?
|
| Mice, Nude | 3 | 2020 | 323 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2015 | 386 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 162 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2010 | 53 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 3 | 2017 | 383 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 1426 | 0.090 |
Why?
|
| Brain | 1 | 2015 | 1268 | 0.080 |
Why?
|
| Solubility | 1 | 2007 | 115 | 0.080 |
Why?
|
| Solvents | 1 | 2007 | 93 | 0.080 |
Why?
|
| Protein Subunits | 1 | 2007 | 85 | 0.080 |
Why?
|
| Molecular Conformation | 1 | 2007 | 150 | 0.080 |
Why?
|
| Protons | 1 | 2007 | 80 | 0.080 |
Why?
|
| Phosphorylation | 3 | 2016 | 878 | 0.070 |
Why?
|
| Protein Binding | 2 | 2020 | 913 | 0.070 |
Why?
|
| Dimerization | 1 | 2006 | 102 | 0.070 |
Why?
|
| Blotting, Western | 3 | 2013 | 834 | 0.070 |
Why?
|
| Membrane Potentials | 1 | 2006 | 213 | 0.070 |
Why?
|
| Amino Acids | 1 | 2006 | 139 | 0.070 |
Why?
|
| Alanine | 1 | 2005 | 28 | 0.070 |
Why?
|
| Threonine | 1 | 2005 | 21 | 0.070 |
Why?
|
| Bacteriorhodopsins | 1 | 2005 | 36 | 0.070 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 85 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 281 | 0.060 |
Why?
|
| Chick Embryo | 2 | 2014 | 71 | 0.060 |
Why?
|
| Carbon | 1 | 2005 | 95 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 2 | 2016 | 33 | 0.060 |
Why?
|
| Oxygen | 1 | 2005 | 193 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2005 | 201 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 1124 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2014 | 392 | 0.060 |
Why?
|
| Fibrin | 1 | 2022 | 8 | 0.060 |
Why?
|
| Patents as Topic | 1 | 2022 | 11 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2022 | 46 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2013 | 309 | 0.050 |
Why?
|
| Quercetin | 2 | 2011 | 41 | 0.050 |
Why?
|
| Enzyme Assays | 1 | 2020 | 11 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2011 | 166 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 1530 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2020 | 212 | 0.040 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 129 | 0.040 |
Why?
|
| Female | 5 | 2020 | 19873 | 0.040 |
Why?
|
| Biocatalysis | 1 | 2017 | 27 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2017 | 103 | 0.040 |
Why?
|
| Hydrolysis | 1 | 2017 | 86 | 0.040 |
Why?
|
| Manganese | 1 | 2017 | 59 | 0.040 |
Why?
|
| Magnesium | 1 | 2017 | 95 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2017 | 97 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2017 | 180 | 0.040 |
Why?
|
| Mice, Hairless | 1 | 2016 | 8 | 0.040 |
Why?
|
| Microtubules | 1 | 2017 | 113 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2017 | 117 | 0.040 |
Why?
|
| Butadienes | 1 | 2016 | 30 | 0.040 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2016 | 22 | 0.040 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2016 | 21 | 0.030 |
Why?
|
| Luciferases | 1 | 2016 | 62 | 0.030 |
Why?
|
| Nitriles | 1 | 2016 | 66 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 485 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2016 | 74 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2016 | 132 | 0.030 |
Why?
|
| Tritium | 1 | 2015 | 48 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 136 | 0.030 |
Why?
|
| Chorioallantoic Membrane | 1 | 2014 | 10 | 0.030 |
Why?
|
| Piperazines | 1 | 2015 | 109 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 87 | 0.030 |
Why?
|
| Colchicine | 1 | 2014 | 15 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 89 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 64 | 0.030 |
Why?
|
| Laminin | 1 | 2014 | 59 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2014 | 46 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 107 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 56 | 0.030 |
Why?
|
| Glycyrrhizic Acid | 1 | 2013 | 3 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2014 | 70 | 0.030 |
Why?
|
| Tubulin | 1 | 2014 | 80 | 0.030 |
Why?
|
| Water | 1 | 2016 | 283 | 0.030 |
Why?
|
| Collagen | 1 | 2014 | 162 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 126 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 247 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 430 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 211 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2013 | 209 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 480 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2014 | 287 | 0.030 |
Why?
|
| Cell Line | 1 | 2016 | 1289 | 0.030 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2011 | 9 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 137 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2011 | 34 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 649 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 164 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 545 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2011 | 92 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 968 | 0.020 |
Why?
|
| Static Electricity | 1 | 2010 | 75 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2010 | 162 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2010 | 186 | 0.020 |
Why?
|
| Ligands | 1 | 2010 | 317 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 859 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 3261 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 1442 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 901 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1317 | 0.020 |
Why?
|
| Male | 1 | 2013 | 18870 | 0.010 |
Why?
|